Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference – Nasdaq
|
Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference
Nasdaq The Company utilizes its expertise in cell engineering to target cancer. Celyad's Natural Killer Receptor based T–Cell (NKR-T) platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, the CAR-T NKR … |
